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Abstract. the expression of claudin-11 in benign and malig-
nant bladder tissue and the effect of forced expression of 
claudin-11 on tight junction function and invasiveness of 
bladder cancer cells were studied. claudin-11 expression 
was tested in bladder cancer cell lines (t24/83, rt 112/84 
and eJ138) using reverse transcription-polymerase chain 
reaction (rt-pcr) and in benign and malignant bladder 
tissue by quantitative rt-pcr and immunohistochemistry. 
t24/83 cells were transfected with the pcDnA.1/nt-gFp-
topo vector containing full-length human claudin-11 
sequence. stable-transfected cells overexpressing claudin-11 
(t24cl-11ex), wild-type cells (t24Wt) and the empty plasmid 
control clone (t24gFp) were compared using transurothelial 
resistance (tUr), in vitro adhesion, invasion and growth 
assays. claudin-11 was strongly expressed in the non-invasive 
rt112/84 cell line compared to the invasive t24/83 and eJ138 
tcc cell lines. Benign bladder tissue demonstrated equal 
expression of claudin-11 mrnA as carcinoma, but displayed 
more intense staining than malignant tissue on immunohis-
tochemistry. Forced-expression of claudin-11 in t24/83 cells 
was confirmed by PCR, immunoprecipitation and by immu-
nofluorescence, which demonstrated increased perinuclear 
claudin-11 staining. Forced expression of claudin-11 did not 
affect tUr (p=0.243), but significantly reduced invasion 
(p=0.001) while increasing cell matrix adhesion (p=0.001) and 
growth rates (p=0.001). the greater expression of claudin-11 in 
benign vs. malignant tissue and non-invasive vs. invasive cell 
lines, and its effect in reducing bladder cancer cell invasiveness 
suggests that claudin-11 may have a role in preventing cancer 
progression and may serve as a therapeutic target in reducing 
metastasis.
Introduction
Bladder cancer is the seventh most commonly diagnosed 
cancer and the eighth most common cause of cancer-related 
death in the UK, accounting for 5002 deaths in 2008 (1). 
In the United states, an estimated 14,680 persons will die 
of bladder cancer in 2010 (2). Approximately 70% of newly 
diagnosed bladder cancers are superficial, low-grade tumors, 
which are managed endoscopically, with or without intra-
vesical chemotherapy or immunotherapy (3). However, up to 
70% of these patients develop tumour recurrence and 10-15% 
progress to muscle-invasive disease requiring radical treat-
ment. Approximately 30% of patients with muscle-invasive 
disease have undetectable metastasis at diagnosis (4), which 
portends a poor prognosis.
Metastasis is a complex process characterised by increased 
tumour cell proliferation and motility, stromal invasion, angio-
genesis, intravasation of cells into the circulation and finally 
extravasation and establishment of distant metastases. A break-
down in the mechanisms controlling normal cell-cell adhesion 
is critical in the growth and progression of cancer. In the normal 
urothelium, tight junctions (tJ) and adherens junctions (AJ) 
play a major role in maintaining cell-cell adhesion. tJs have 
a number of diverse functions including the maintenance 
of transepithelial resistance and the control of paracellular 
permeability across epithelial surfaces (5,6), the maintenance 
of cell polarity (7), cell signalling and cytoskeletal regulation 
(8) and cell growth and differentiation (9). In the mammalian 
bladder tJs consist of 4-6 interconnecting strands that 
obliterate the intercellular space (10). the tJs are made up 
of the transmembrane proteins (including occludin and the 
claudins) that form the tJ strands and the peripheral plaque 
proteins (Zo-1, Zo-2, Zo-3, AF6 and MUpp-1) that bind 
the transmembrane proteins with the cytoskeleton (11). the 
claudins define the permeability characteristics of epithelial 
and endothelial tissues (6).
Although previous reports have described the tissue distri-
bution of claudins and their altered expression in a number 
of cancers (12), there are few reports on their expression in 
the urothelium. claudins-4, -8 and -12 were expressed in the 
umbrella cell tJs of murine epithelium (13), while claudins-3, -4, 
-5 and -7 were expressed in human urothelium (14). claudin-4 
expression was downregulated in bladder cancer compared 
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to normal urothelium and it localised to the cytoplasm rather 
than the cell membrane in the cancer cells (15). We analyzed 
the expression of a number of claudins in tcc cell lines and in 
bladder tissue. since the expression of claudin-11 was decreased 
in the invasive cell lines compared to the non-invasive ones, and 
in tcc tissue as compared to benign urothelium, we proceeded 
to force express claudin-11 in the invasive t24/83 cell line to 
determine its effect on cell function.
Materials and methods
Materials. three bladder cancer cell lines (the low-grade 
rt112/84, and the high-grade invasive cell lines t24/83 and 
eJ138) were obtained from the european collection of Animal 
cell culture (ecAcc, salisbury, UK) and maintained in 
Dulbecco's modified eagle's medium/Ham's F-12 medium 
supplemented with 10% heat-inactivated foetal calf serum, 
benzyl-penicillin and streptomycin. primers (Invitrogen, 
paisley, UK) and anti-claudin-11 and anti-Zo-1 antibodies 
(santa cruz Biotechnology, santa cruz, UsA) were used in the 
study.
Immunohistochemical staining of frozen bladder specimens. 
snap-frozen bladder tissue samples (cancer and benign back-
ground) were obtained from patients undergoing transurethral 
resection of bladder tumour or radical cystectomy following 
ethics committee approval and written, informed consent. All 
biopsies were also histopathologically evaluated to confirm if 
they were cancer or benign tissue.
We used a previously reported protocol to stain bladder 
tissue specimens for claudin-11 with anti-claudin-11 rabbit 
antibody (1:100 dilution) (16,17). the staining intensity in 
benign and malignant tissue was quantified using Optimas 6.0 
software and compared as previously described (17,18). 
RNA isolation and RT-PCR. rnA was extracted using total 
rnA isolation reagent (ABgene™, epsom, surrey, UK). 
rt was performed using an enhanced Avian Hs reverse 
transcriptase-pcr kit (sigma-Aldrich, Dorset, UK) followed 
by pcr (reDtaq™ readyMix™ pcr reaction mix, sigma- 
Aldrich). primer sequences are listed in table I. cycling 
conditions were 94˚C for 5 min, 36 cycles of 94˚C for 15 sec, 
55˚C for 15 sec, 72˚C for 15 sec, followed by 72˚C for 7 min. 
the pcr products were visualized on 2% agarose gel stained 
with ethidium bromide (predicted size; claudin-11: 100 bp; 
β-actin: 580 bp).
Quantitative RT-PCR. Q-rt-pcr was performed on bladder 
tissue samples with the Amplifluor™ Uniprimer™ system 
(Intergen company, oxford, UK) using the icycler IQ system 
(Bio-rad laboratories, Hemel Hempstead, UK) to detect the 
expression of claudin-11 (results expressed as sample copy 
number). Use of standard amount (250 ng) of rnA for all 
samples, and the detection of cK-19 copy number within 
these samples were used to normalise the samples, based on 
previous reports from the host laboratory (16-18). the results 
were expressed as a ratio of the copy number of claudin-11 
to cK-19 in benign and cancer tissue. primer sequences are 
described in table I.
Forced overexpression of claudin-11 in T24/83 cells. expression 
primers (cldn11exF3 + cldn11exr1; predicted size 623 bp) 
were designed using the Beacon Designer software programme 
(premier Biosoft International, palo Alto, cA, UsA) to amplify 
the full coding region of human claudin-11 based on the Homo 
sapiens claudin-11 (pubMed accession no. nM1001346) 
mrnA sequence and are described in table I. Full length 
claudin-11 was cloned into the pcDnA3.1/nt-gFp-topo 
tA expression kit (Invitrogen, paisley, scotland, UK), the 
direction and sequence of the insert verified and the plasmid 
was extracted. the claudin-11 expression cassette and an 
empty plasmid was transfected into wild-type t24/83 tcc 
cells (t24Wt) using an easyjet plus® electroporator to produce 
the t24cldn-11ex and t24gFp clones respectively, which were 
incubated in g418 selection medium.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
and Western blot. the protein concentration in cell lysates was 
quantified using a DC Protein Assay kit (Bio-Rad™). Equal 
amounts of protein were separated by sDs-pAge, blotted 
onto nitrocellulose sheets and probed with anti-claudin-11 
primary and peroxidise-conjugated secondary antibodies. 
the protein bands were visualized by a supersignal™ system 
and the images documented using the UvIprochemi system 
(UvItec, cambridge, UK).
Immunoprecipitation. Immunoprecipitation was used to detect 
differences in expression of claudin-11 in the wild-type and 
transformed cell lines, since the results of sDs-pAge Western 
blotting were equivocal even after using claudin antibodies 
reacting to different epitopes. Anti-claudin-11 antibody was 
added to the cell lysates and the antigen-antibody complexes 
thus formed were mopped up by a mixture of staphylococcal 
protein A and protein g beads, which are covalently bound to 
sepharose or agarose. these immunocomplexes were sepa-
rated out by precipitation, followed by sDs-pAge, and then 
immuno-probed with secondary antibodies and the bands 
visualised as above.
Immunofluorescent staining of bladder cancer cells. t24Wt, 
t24gFp and t24cldn-11exp cells were grown to confluence in 
16-well chamber slides (lab-tek®, nalge-nunc Inc., naperville, 
table I. pcr primer sequences.
 sense primer Anti-sense primer
claudin-11 ccggtgtggctaagtaca actgaacctgaccgtacacacacagggaaccagatg
cK19 caggtccgaggttactgac actgaacctgaccgtacacagtttctgccagtgtgtcttc
Actin caggaggttgaaggactaaa gggatcagttttctttgtca
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USA), fixed in methanol at -20˚C, washed with TBS, and 
permeabilised with 0.1% Triton X-100 for 1 min. Non-specific 
binding sites were blocked with 10% horse serum for 60 min. 
the cells were incubated with anti-claudin-11 or anti-Zo-1 
primary antibodies (1:300 dilution), followed by tetramethyl-
rhodamine isothyocyanate (trItc)-conjugated secondary 
antibody, mounted using Fluorsave™ and visualized under a 
fluorescent microscope. 
Transurothelial resistance (TUR). tUr was measured using 
a previously described method (19). A 24-well plate with 
0.4-µM pore size cell culture inserts (costar®, corning Inc., 
NY, USA) was used to grow a confluent layer of each cell type 
(t24Wt, t24gFp, t24cl11ex) using 105 cells and the medium was 
then changed. resistance was measured using an evoM™ 
voltohmometer (World precision Instruments, Fl, UsA) 
equipped with a pair of costar electrodes at baseline (0 min), 
30 min, 1, 2 and 4 h. results were expressed as a change in 
tUr from the value at baseline. statistics were calculated 
using repeated measures AnovA. 
In vitro invasion assay. this was performed as previously 
reported and modified in our laboratory (16,17, by adding a 
total of 10,000 cells to each insert and incubating for 96 h. 
cells that had invaded Matrigel™ matrix (BD Biosciences, 
Bedford, MA, UsA) were stained with crystal violet, the 
dye extracted using 10% (v/v) acetic acid and absorbances 
obtained using a multiplate reader (16,17). 
Cell matrix adhesion assay. A 96-well tissue culture plate was 
coated with 1 µg/well of Matrigel, the wells were blocked with 
5% BsA (bovine serum albumin) in sterile Bss (balanced 
salt solution), and 10,000 of the respective cells were added 
to each well. After 40 min of incubation, non-adherent cells 
were washed off using Bss. Adherent cells were stained with 
Mtt and staining was determined by measuring absorbance 
on a plate reading spectrophotometer (Bio-tek elx 800, Wolf 
laboratories, york, UK). 
In vitro cell growth assay. this assay was based on a method 
previously reported by the host laboratory (16,17). two thou-
sand cells of each type were incubated in a 96-well plate and 
their growth assessed at days one and five. the cells were 
stained with crystal violet and absorbance determined using a 
spectrophotometer. Absorbances represented the cell number, 
and the percentage change in absorbance at day five compared 
to day one represented the corresponding change in the number 
of cells. 
Statistical analysis. spss® version 16 was used for analysis. 
Kolmogorov-smirnov assumptions of normality and homo-
geneity of variances using the levene statistic were tested. 
AnovA was used to compare the means between groups 
with Bonferroni post hoc comparisons used to determine the 
statistical difference between the groups. Differences were 
considered statistically significant at p<0.05.
Results
Expression of claudin-11 in T24/83, RT112/84 and EJ 138 
bladder cancer cell lines. claudin-11 was strongly expressed 
in the non-invasive rt112/84 cell line, while it was only 
weakly expressed in the invasive t24/83 and eJ138 tcc cell 
lines (Fig. 1A). since the expression of claudin-11 in non-
invasive and invasive cell lines was not equal, its expression 
in benign and malignant bladder tissue was investigated to 
determine any differences in expression and based on these 
results, we forced-expressed claudin-11 in the invasive t24/83 
tcc cell line.  
Expression of claudin-11 in benign and malignant bladder 
tissue
Expression of claudin-11 mRNA in bladder tissue. eight 
benign and 17 tcc bladder tissue samples were available 
for Q-RT-PCR. There was no significant difference (p=0.317, 
two-tailed t-test) in the claudin-11/cK-19 transcript ratio 
between benign (mean ± seM, 3.81±0.43) and tcc bladder 
(4.36±0.31) tissue, implying that there was no significant differ-
Figure 1. (A) rt-pcr shows claudin-11 expression in t24/83, rt112/84 and 
eJ138 bladder cancer cell lines. expression was higher in the non-invasive 
rt112/84 cell line compared to the invasive (t24/83 and eJ138) cell lines. 
pos., positive; neg., negative. (B) Forced over-expression of claudin-11 in 
t24/83 cells: rt-pcr demonstrating that claudin-11 mrnA expression was 
increased in t24cldn-11ex compared to t24Wt and t24gFp cells. (c) Western 
blot reveals that claudin-11 protein was not detected in any of the three types 
of cells studied. MW, molecular weight. (D) Immunoprecipitation demon-
strating increased expression of claudin-11 protein in t24cldn-11ex compared 
to t24Wt and t24gFp cells.
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ence in the expression of claudin-11 mrnA between benign 
and tcc tissue.
Immunohistochemical expression of claudin-11 protein 
in bladder tissue. eight benign and 19 (9 non-invasive and 
10 invasive) tcc bladder tissue samples were stained for 
claudin-11 (Fig. 2A), which demonstrated that claudin-11 
located to all layers of the urothelium, but was particularly 
strongly expressed in the umbrella cell layer. claudin-11 
mainly located to the intercellular region (tJ), but was also 
demonstrated a cytoplasmic distribution. Quantitative analysis 
of claudin-11 staining intensity (Fig. 2B) demonstrated that 
the expression of claudin-11 was significantly greater in 
benign (mean ± seM, 75.9±5.02) compared to all cancer 
(36.53±2.96) samples (p<0.0001, two-tailed t-test), and 
to non-invasive (40.61±4.64) and invasive (32.85±3.68) 
cancer samples (p<0.0001, ANOVA test). Post-hoc analysis 
using Bonferoni test showed significant difference in staining 
intensity between benign and non-invasive cancer (p<0.001) 
and between benign and invasive cancer tissue (p<0.001) but 
no difference between the non-invasive and invasive cancer 
samples (p=0.618). thus claudin-11 protein expression was 
significantly greater in benign bladder tissue compared to 
tcc. 
Forced overexpression of claudin-11 in T24/83 cells. since the 
expression of claudin-11 was decreased in tcc bladder tissue 
compared to benign samples, and in the invasive tcc cell 
lines compared to the moderately differentiated rt112/84 cell 
line, we forced expressed claudin-11 in the t24/83 cell line, 
which was derived from a patient with poorly differentiated 
recurrent invasive bladder tcc. t24cldn-11ex cells demonstrated 
increased expression of claudin-11 (Fig. 1B) mrnA compared 
to wild-type (t24Wt) and empty plasmid containing cells 
(t24gFp). Western blotting failed to demonstrate specific 
claudin-11 bands, but immunoprecipitation using claudin-11 
antibody demonstrated increased expression of claudin-11 
protein in t24cldn-11ex cells compared to t24Wt and t24gFp 
(Fig. 1C and D). Immunofluorescence confirmed increased 
Figure 2. representative images of claudin-11 immunohistochemical analysis comparing staining patterns and intensity in benign, non-invasive and invasive 
bladder cancer tissue. (A) there was greater uptake in benign tissue as compared to tcc. claudin-11 located to the intercellular region and cytoplasm of cells 
(x400 magnification). (B) Claudin-11 staining intensity was greater in benign bladder tissue, compared to non-invasive, invasive and all cancer tissue. *p<0.05. 
error bars represent seM.
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expression of claudin-11 protein in the t24cldn-11ex cell line 
compared to controls (Fig. 3A). this mainly located to the 
cytoplasm and perinuclear region rather than the intercellular 
region (tJ). staining for Zo-1 demonstrated intercellular 
staining (tJ). 
Effect of claudin-11 forced expression on transurothelial 
resistance. Forced expression of claudin-11 or incorporation 
of GFP plasmid into T24/83 bladder cancer cells had no signifi-
cant effect (p=0.243, repeated measures AnovA) on tUr, 
when measured over 240 min. Fig. 3B shows the mean change 
in tUr from baseline over 240 min for the t24 cell line.
Effect of claudin-11 forced expression on cell growth. Forced 
expression of claudin-11 (t24cldn-11ex) significantly increased 
(p=0.001, AnovA, Fig. 4A and B) the growth of t24/83 
bladder cancer cells compared to the t24Wt and t24gFp cells 
at day 5. there was however, no difference between t24Wt and 
t24gFp cells (p=1.000). Fig. 4B shows the percentage change in 
absorbance (cell numbers) after 5 days in the t24 cell line. 
Effect of claudin-11 forced expression on Matrigel invasion. 
the technique of in vitro cell matrix invasion involves 
staining the cells invading through the cell matrix following 
96 h of incubation, with crystal violet and measuring the 
absorbance of the dye, which is proportional to the number 
of cells invading through Matrigel. There was a significant 
decrease (p=0.001, AnovA, Fig. 4c) in the invasiveness 
of t24cldn-11ex cells (mean ± seM, 1.54±0.19) compared 
to t24Wt (2.55±0.33) and t24gFp (2.84±0.31). there was 
however, no difference between t24Wt and t24gFp cells 
(p=1.000).
Any change in invasion (cell count) between the control 
and genetically manipulated groups could either be due to 
the effect of genetic manipulation on cell growth or on its 
invasive capacity per se. since the growth assay revealed that 
forced expression of claudin-11 (t24cldn-11ex) significantly 
increased their growth rate compared to controls, the signifi-
cant reduction in invasiveness elicited by forced-expression of 
claudin-11 in t24/83 cells compared to controls may actually 
underestimate the true effects.
Figure 3. (A) Representative images of immunofluorescence staining for claudin-11 and ZO-1 in T24/83 cells (x40 magnification). There was a stronger 
signal for claudin-11 in t24cldn-11ex compared to t24Wt and t24gFp cells, thus confirming its forced expression. ZO-1 located to tight junctions (white arrows), 
whereas claudin-11 located to cytoplasm (white arrowheads). (B) effect of forced-expression of claudin-11 on transurothelial resistance (change from base-
line) of T24/83 cells over 240 min. There was no significant difference in the change in TUR in T24cldn-11ex cells compared to t24Wt or t24gFp cells (p=0.243, 
AnovA test). error bars represent seM. (c) the statistical information of the data set.
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Effect of claudin-11 forced expression on cell matrix adhesion. 
There was a significant increase (p= 0.001, ANOVA, Fig. 4D) in 
the adhesion of t24cldn-11ex cells (mean ± seM, 0.144±0.009) 
to Matrigel compared to t24Wt (0.113±0.012) and t24gFp 
(0.107±0.010). there was however, no difference between 
t24Wt and t24gFp cells (p=1.000).
Discussion
the tJ of the umbrella cell layer of the urothelium create 
the paracellular barrier protecting the underlying detrusor 
against exposure from urinary toxins, with the claudins 
thought to play a central role in the maintenance of this barrier 
(6). Disruptions of tJs with loss of tJ proteins including 
claudins are thought to reduce cell-cell adhesion and lower 
the diffusion barrier resulting in an abnormal influx of growth 
factors and nutrients, which offers a selective advantage to 
developing tumour cells (20). Altered expression of various 
claudins has been reported in several cancer types (12) with 
an inverse correlation reported with histological grade (21) 
and invasiveness (22). conversely, expression of claudin-3 and 
-4 positively correlates with invasiveness of ovarian cancer 
cells (23). claudin-11 has been reported to be expressed in a 
number of tissues including the nephron, oligodendrocytes, 
sertoli cells and basal cells of the inner ear (24-26) but not 
previously noted in the urothelium. In the present study, 
claudin-11 expression was decreased in invasive compared 
to non-invasive tcc cell lines. the expression of claudin-11 
protein was decreased in tcc tissue compared to benign 
urothelium, although the expression of claudin-11 mrnA was 
equal in both. this may be due to post-transcriptional and 
post-translational mechanisms, including histone modification, 
as has been noted in breast cancer cells where the amount of 
claudin-1 protein but not mrnA increases as the number of 
cell contact sites increase (12). In the present study, benign 
and non-invasive bladder tissue samples showed better formed 
tJs compared to the invasive samples, possibly explaining the 
greater degree of claudin-11 expression in the former.
Although Western blotting could not demonstrate forced-
expression of claudin-11 in t24/83, this was confirmed 
by the more sensitive immunoprecipitation technique. 
Immunofluorescence studies revealed that claudin-11 located 
to the peri-nuclear rather than the inter-cellular regions (where 
Zo-1 signal was detected), suggesting that claudin-11 may not 
behave like a classic tJ protein in tcc cells. claudin-4 expres-
sion was decreased and reported to delocalise to the cytoplasm 
in human bladder tumours and the bladder tumour cell line 
Ht-1376 (15). similarly, claudin-1 was noted along the entire 
lateral membrane as well as in the cytoplasm of breast cancer 
cells in tissues (27).
Forced-expression of claudin-11 did not affect tUr of 
T24/83 cells. This finding is in agreement with the results 
of immunofluorescent staining suggesting that claudin-11 
introduced via plasmid into t24/83 cells was not incorporated 
into tJs, and hence possibly did not affect tUr. on the other 
hand, claudin-11 decreased invasion of t24/83 cells through 
the basement membrane, while increasing their adhesiveness 
and growth rate. similarly, forced-expression of claudin-16 
in the MDA-MB-231 breast cancer cell line increased their 
adhesiveness while decreasing invasiveness (28). Although 
the exact mechanism is unknown, other tJ proteins such as 
claudin-3 and -4 increase motility and invasion in ovarian 
surface epithelial cells by activating matrix metalloprotei-
nase-2 (23), while Zo-1 regulates cell proliferation (9). the 
results of the functional assays suggest a role for claudin-11 
in maintaining tissue barriers, in accord with other reports. 
thus, claudin-11 null mice demonstrated hind limb weakness 
with slowed nerve conduction, impaired spermatogenesis and 
hearing loss as a result of impaired tissue barrier function 
(24,25).
Figure 4. effect of forced-expression of claudin-11 on t24/83 cells. (A and B) Day 5 change in absorbance, representing percentage change in cell number 
compared to day 1. claudin-11 forced-expression (t24cldn-11ex) significantly increased cell growth compared to T24Wt and t24gFp cells. *p<0.05. (C) Invasiveness 
of t24cldn-11ex was significantly reduced compared to T24Wt and t24gFp cells. (D) cell matrix adhesion of t24cldn-11ex was significantly increased compared to 
t24Wt and t24gFp cells. error bars represent seM.
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this study is limited by the use of a small number of bladder 
tissue samples. Further studies must be performed using a large 
number of samples to confirm the expression of claudin-11 by 
Western blotting and immunohistochemistry. the suppression 
of the invasive phenotype by claudin-11 noted in this study 
needs to be confirmed in vivo and the signalling pathways 
involved are yet to be identified. 
this study demonstrates the role of claudin-11 in bladder 
cancer cells. claudin-11 expression could potentially be used 
as a biomarker to differentiate between non-invasive and 
aggressive bladder cancer. In vivo efficacy and safety studies 
must be performed to explore if claudin-11 gene therapy could 
be used to modify the course of the disease since this therapy 
can be delivered urethrally directly into the bladder. 
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